$60,000 of REGENXBIO INC. lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues."
You can find more data on corporate lobbying on Quiver Quantitative.
RGNX Insider Trading Activity
RGNX insiders have traded $RGNX stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $RGNX stock by insiders over the last 6 months:
- CURRAN SIMPSON (Chief Executive Officer) has made 0 purchases and 3 sales selling 36,169 shares for an estimated $416,598.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
RGNX Hedge Fund Activity
We have seen 86 institutional investors add shares of RGNX stock to their portfolio, and 63 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. removed 797,100 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $7,692,015
- MORGAN STANLEY added 709,512 shares (+71.3%) to their portfolio in Q3 2025, for an estimated $6,846,790
- ASSENAGON ASSET MANAGEMENT S.A. added 454,977 shares (+64.5%) to their portfolio in Q4 2025, for an estimated $6,551,668
- INVENOMIC CAPITAL MANAGEMENT LP added 426,904 shares (+inf%) to their portfolio in Q3 2025, for an estimated $4,119,623
- RENAISSANCE TECHNOLOGIES LLC removed 425,714 shares (-57.9%) from their portfolio in Q3 2025, for an estimated $4,108,140
- INTEGRAL HEALTH ASSET MANAGEMENT, LLC added 400,000 shares (+57.1%) to their portfolio in Q3 2025, for an estimated $3,860,000
- BLACKROCK, INC. removed 388,200 shares (-5.7%) from their portfolio in Q3 2025, for an estimated $3,746,130
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
RGNX Analyst Ratings
Wall Street analysts have issued reports on $RGNX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 12/19/2025
- Chardan Capital issued a "Buy" rating on 11/20/2025
- RBC Capital issued a "Outperform" rating on 11/07/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/07/2025
- Barclays issued a "Overweight" rating on 08/08/2025
To track analyst ratings and price targets for RGNX, check out Quiver Quantitative's $RGNX forecast page.
RGNX Price Targets
Multiple analysts have issued price targets for $RGNX recently. We have seen 6 analysts offer price targets for $RGNX in the last 6 months, with a median target of $35.5.
Here are some recent targets:
- Annabel Samimy from Stifel set a target price of $45.0 on 12/19/2025
- Mani Foroohar from Leerink Partners set a target price of $20.0 on 12/15/2025
- Daniil Gataulin from Chardan Capital set a target price of $52.0 on 11/20/2025
- Luca Issi from RBC Capital set a target price of $19.0 on 11/07/2025
- Yi Chen from HC Wainwright & Co. set a target price of $34.0 on 10/07/2025
- Gena Wang from Barclays set a target price of $37.0 on 08/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
